Sameer J. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sameer J. Patel has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Haomiao Jia
School of Nursing, Columbia University Medical Center, and
2 shared publicationsLisa Saiman
Department of Pediatrics, Columbia University Medical Center, New York, New York
2 shared publicationsLuis Alba
Department of Pediatrics, Columbia University Medical Center, New York, New York
2 shared publicationsSarah A. Clock
Department of Pediatrics, Columbia University Medical Center, New York, New York
2 shared publicationsShan Sun
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
2 shared publicationsSimon Parzen-Johnson
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
2 shared publications
Latest Publications
- 16 December 2022
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 19 (2) , 194.e1-194.e8
Prospective evaluation of a pediatric urodynamics protocol before and after limiting urine cultures
- 16 December 2022
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 19 (2) , 194.e1-194.e8
Prospective evaluation of a pediatric urodynamics protocol before and after limiting urine cultures
- Open Access
- 1 December 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (12) , e2248671
Sociodemographic Comparison of Children With High-risk Medical Conditions Referred vs Identified Through Screening Plus Outreach for COVID-19 Therapeutics
Medications to treat COVID-19 such as monoclonal antibodies (mAb) and antivirals (remdesivir, nirmatrelvir/ritonavir) are effective in reducing risk of hospitalization and death in high-risk populations.1 By December 2021, multiple medications to treat mild to moderate COVID-19 in adults and adolescents were authorized by the Food and Drug Administration (FDA), but supply was limited relative to demand due to the surge in cases caused by the Omicron variant.2-4 Despite direct distribution by the federal government and local health departments, racial and ethnic disparities in receiving treatments have been documented, along with lower access to mAb for patients living in socially vulnerable communities.5,6 Patients with lower socioeconomic status (SES) and less English proficiency have also faced substantial barriers to other COVID-19 mitigation measures, including vaccination, despite their association with higher COVID-19 morbidity and mortality.7,8
- 1 December 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (12) , e2248671
Open AccessSociodemographic Comparison of Children With High-risk Medical Conditions Referred vs Identified Through Screening Plus Outreach for COVID-19 Therapeutics
Medications to treat COVID-19 such as monoclonal antibodies (mAb) and antivirals (remdesivir, nirmatrelvir/ritonavir) are effective in reducing risk of hospitalization and death in high-risk populations.1 By December 2021, multiple medications to treat mild to moderate COVID-19 in adults and adolescents were authorized by the Food and Drug Administration (FDA), but supply was limited relative to demand due to the surge in cases caused by the Omicron variant.2-4 Despite direct distribution by the federal government and local health departments, racial and ethnic disparities in receiving treatments have been documented, along with lower access to mAb for patients living in socially vulnerable communities.5,6 Patients with lower socioeconomic status (SES) and less English proficiency have also faced substantial barriers to other COVID-19 mitigation measures, including vaccination, despite their association with higher COVID-19 morbidity and mortality.7,8
- 1 October 2021
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (10) , 1681-1688
Use of the Electronic Health Record to Optimize Antimicrobial Prescribing
- 1 October 2021
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (10) , 1681-1688
Use of the Electronic Health Record to Optimize Antimicrobial Prescribing
- 1 June 2021
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 147 (6)
Short-Duration Electronic Health Record Option Buttons to Reduce Prolonged Length of Antibiotic Therapy in Outpatients
BACKGROUND: Prolonged antibiotic therapy may be associated with increased adverse events and antibiotic resistance. We deployed an intervention in the electronic health record (EHR) to reduce antibiotic duration for pediatric outpatients. METHODS: A preintervention and postintervention interrupted time series analysis of antibiotic duration for 7 antibiotics was performed for patients discharged from the ED and clinics of a children’s hospital network from 2012 to 2018. In February 2015, clickable 5- and 7-day duration option buttons were deployed in the EHR for clindamycin, cephalexin, ciprofloxacin and levofloxacin, trimethoprim-sulfamethoxazole, amoxicillin, and cefdinir, with an additional 10-day option for the latter 2. Prescribers were able to enter a free-text duration. The option buttons were not announced, and were not linked to a specific diagnosis or quality improvement initiative. The primary outcome was proportion of prescriptions per month with duration of 10 days. Balancing secondary outcomes were reorders of the same agent, return to clinic, and inpatient admissions within 30 days. RESULTS: There were 54 315 prescriptions for the 7 antibiotics associated with 39 894 patients, 18 683 clinic visits, and 35 632 ED visits. Overall, a −5.1% (95% confidence interval [CI], −8.3% to −2.0%) change in the proportion of prescriptions with a 10-day duration was attributable to the intervention, with larger effects noted for clindamycin (−20.8% [95% CI, −26.9% to −14.7%]) and cephalexin (−9.9% [95% CI, −14.3% to −5.4%]). There was no increase in the reorders of the same agent, return clinical encounters, or inpatient admissions within 30 days. CONCLUSIONS: A simple intervention in the EHR can safely reduce duration of antibiotic therapy.
- 1 June 2021
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 147 (6)
Short-Duration Electronic Health Record Option Buttons to Reduce Prolonged Length of Antibiotic Therapy in Outpatients
BACKGROUND: Prolonged antibiotic therapy may be associated with increased adverse events and antibiotic resistance. We deployed an intervention in the electronic health record (EHR) to reduce antibiotic duration for pediatric outpatients. METHODS: A preintervention and postintervention interrupted time series analysis of antibiotic duration for 7 antibiotics was performed for patients discharged from the ED and clinics of a children’s hospital network from 2012 to 2018. In February 2015, clickable 5- and 7-day duration option buttons were deployed in the EHR for clindamycin, cephalexin, ciprofloxacin and levofloxacin, trimethoprim-sulfamethoxazole, amoxicillin, and cefdinir, with an additional 10-day option for the latter 2. Prescribers were able to enter a free-text duration. The option buttons were not announced, and were not linked to a specific diagnosis or quality improvement initiative. The primary outcome was proportion of prescriptions per month with duration of 10 days. Balancing secondary outcomes were reorders of the same agent, return to clinic, and inpatient admissions within 30 days. RESULTS: There were 54 315 prescriptions for the 7 antibiotics associated with 39 894 patients, 18 683 clinic visits, and 35 632 ED visits. Overall, a −5.1% (95% confidence interval [CI], −8.3% to −2.0%) change in the proportion of prescriptions with a 10-day duration was attributable to the intervention, with larger effects noted for clindamycin (−20.8% [95% CI, −26.9% to −14.7%]) and cephalexin (−9.9% [95% CI, −14.3% to −5.4%]). There was no increase in the reorders of the same agent, return clinical encounters, or inpatient admissions within 30 days. CONCLUSIONS: A simple intervention in the EHR can safely reduce duration of antibiotic therapy.
- 1 September 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (9) , 1630-1636
Clinical Performance and Impact of Accelerate Pheno for Gram-negative Bacteremia in Hospitalized Children
- 1 September 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (9) , 1630-1636
Clinical Performance and Impact of Accelerate Pheno for Gram-negative Bacteremia in Hospitalized Children
- Top Cited Papers
- 1 September 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (9) , 1649-1658
Antibiotic Stewardship in Food-producing Animals: Challenges, Progress, and Opportunities
- 1 September 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (9) , 1649-1658
Top Cited PapersAntibiotic Stewardship in Food-producing Animals: Challenges, Progress, and Opportunities
- 15 May 2020
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 135, 110115
Resource utilization of intraoperative cultures for pediatric deep neck space abscesses
- 15 May 2020
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 135, 110115
Resource utilization of intraoperative cultures for pediatric deep neck space abscesses
- 7 April 2019
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 55 (4) , 483
Probiotics and acute gastroenteritis
- 7 April 2019
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 55 (4) , 483
Probiotics and acute gastroenteritis
- Open Access
- 1 August 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (8) , 4896-4900
Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients
The rising incidence of Clostridium difficile infections (CDIs) in adults is partly related to the global spread of fluoroquinolone-resistant strains, namely, BI/NAP1/027. Although CDIs are also increasingly diagnosed in children, BI/NAP1/027 is relatively uncommon in children. Little is known about the antibiotic susceptibility of pediatric CDI isolates. C. difficile was cultured from tcdB -positive stools collected from children diagnosed with CDI between December 2012 and December 2013 at an academic children's hospital. CDI isolates were grouped by restriction endonuclease analysis (REA). MICs were measured by agar dilution method for 7 antibiotics. Susceptibility breakpoints were based on guidelines from CLSI and/or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). MICs and REA groupings of C. difficile isolates from 74 adult patients (29 isolates underwent REA) from a temporally and geographically similar adult cohort were compared to those of pediatric isolates. Among 122 pediatric and 74 adult isolates, respectively, the rates of resistance were as follows: metronidazole, 0% and 0%; vancomycin, 0% and 8% ( P = 0.003); rifaximin, 1.6% and 6.7% ( P = 0.11); clindamycin, 18.9% and 25.3% ( P = 0.29); and moxifloxacin, 2.5% and 36% ( P = P = <0.0001). The 3 moxifloxacin-resistant pediatric isolates were of REA groups BI and CF and a nonspecific group. The 2 rifaximin-resistant pediatric isolates were of REA groups DH and Y. The 21 clindamycin-resistant pediatric isolates were distributed among 9 REA groups (groups A, CF, DH, G, L, M, and Y and 2 unique nonspecific REA groups). These data suggest that a diverse array of relatively antibiotic-susceptible C. difficile strains predominate in a cohort of children with CDI compared to adults.
- 1 August 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (8) , 4896-4900
Open AccessDifferences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients
The rising incidence of Clostridium difficile infections (CDIs) in adults is partly related to the global spread of fluoroquinolone-resistant strains, namely, BI/NAP1/027. Although CDIs are also increasingly diagnosed in children, BI/NAP1/027 is relatively uncommon in children. Little is known about the antibiotic susceptibility of pediatric CDI isolates. C. difficile was cultured from tcdB -positive stools collected from children diagnosed with CDI between December 2012 and December 2013 at an academic children's hospital. CDI isolates were grouped by restriction endonuclease analysis (REA). MICs were measured by agar dilution method for 7 antibiotics. Susceptibility breakpoints were based on guidelines from CLSI and/or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). MICs and REA groupings of C. difficile isolates from 74 adult patients (29 isolates underwent REA) from a temporally and geographically similar adult cohort were compared to those of pediatric isolates. Among 122 pediatric and 74 adult isolates, respectively, the rates of resistance were as follows: metronidazole, 0% and 0%; vancomycin, 0% and 8% ( P = 0.003); rifaximin, 1.6% and 6.7% ( P = 0.11); clindamycin, 18.9% and 25.3% ( P = 0.29); and moxifloxacin, 2.5% and 36% ( P = P = <0.0001). The 3 moxifloxacin-resistant pediatric isolates were of REA groups BI and CF and a nonspecific group. The 2 rifaximin-resistant pediatric isolates were of REA groups DH and Y. The 21 clindamycin-resistant pediatric isolates were distributed among 9 REA groups (groups A, CF, DH, G, L, M, and Y and 2 unique nonspecific REA groups). These data suggest that a diverse array of relatively antibiotic-susceptible C. difficile strains predominate in a cohort of children with CDI compared to adults.